⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23057937 | 0.81 | — | — | |
| SCHEMBL19021436 | 0.77 | — | — | |
| SCHEMBL13805893 | 0.72 | — | — | |
| SCHEMBL23057873 | 0.69 | — | — | |
| SCHEMBL18681423 | 0.64 | DGAT1 (0.32) | — | |
| SCHEMBL25879618 | 0.64 | PIK3CD (0.33) | — | |
| SCHEMBL19010110 | 0.62 | GRM5 (0.35) | — | |
| SCHEMBL12147343 | 0.62 | — | — | |
| SCHEMBL20328039 | 0.61 | PIK3CD (0.39) | — | |
| SCHEMBL19010103 | 0.60 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11713322-B2 | Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer | CAPELLA THERAPEUTICS, INC. (US) | 2023-08-01 | — | — | US | disclosed |
| US-11713322-B2 | Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer | CAPELLA THERAPEUTICS, INC. (US) | 2023-08-01 | — | — | US | disclosed |
| US-11242352-B2 | Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer | CAPELLA THERAPEUTICS, INC. (US) | 2022-02-08 | — | — | US | disclosed |
| US-20210061816-A1 | BENZIMIDAZOLE DERIVATIVES AS ERBB TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER | CAPELLA THERAPEUTICS, INC. (US) | 2021-03-04 | — | — | US | disclosed |
| US-10683304-B2 | Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer | CAPELLA THERAPEUTICS, INC. (US) | 2020-06-16 | — | — | US | disclosed |
| US-10590108-B2 | Benzimidazoles for use in the treatment of cancer and inflammatory diseases | CAPELLA THERAPEUTICS, INC. (US) | 2020-03-17 | — | — | US | disclosed |
| US-20190169204-A1 | BENZIMIDAZOLE DERIVATIVES AS ERBB TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER | CAPELLA THERAPEUTICS, INC. | 2019-06-06 | — | — | US | disclosed |
| US-10202398-B2 | Benzimidazole derivatives as ERBB tyrosine kinase inhibitors for the treatment of cancer | CAPELLA THERAPEUTICS, INC. (US) | 2019-02-12 | — | — | US | disclosed |
| US-20170174697-A1 | BENZIMIDAZOLE DERIVATIVES AS ERBB TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER | CAPELLA THERAPEUTICS, INC. | 2017-06-22 | — | — | US | disclosed |
| US-20170174697-A1 | BENZIMIDAZOLE DERIVATIVES AS ERBB TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF CANCER | CAPELLA THERAPEUTICS, INC. | 2017-06-22 | — | — | US | disclosed |